Early treatment with combo may be key The first study, led by researchers at Imperial College London as part of an ongoing international platform trial, involved randomly assigning 803 patients in 113 intensive care units (ICUs) in six countries to receive tocilizumab, sarilumab, or usual care from April (tocilizumab) and June (sarilumab) through November 2020. Median number of organ support–free days was 10 in the group receiving tocilizumab (353 patients), 11 in the sarilumab group (48 patients), and 0 in the control group (402 patients). Both monoclonal antibodies showed effectiveness in improving 90-day survival, time to ICU and hospital release, and World Health Organization ordinal clinical status scale on day 14.

 

Doctor and nurse takecare of Infected covid19 patient. Case from coronavirus social issue of world problem. Medical teamwork helping to find vaccine and solution concept.

Read more CIDRAP…